RxDoctor Payments Data

David Francis, MD

Family Medicine · Decatur, ALNPI 1427062173

Payments from drug & device makers

$1,767in general payments, 2019–2025

Across 97 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$518
  • AbbVie$149
  • Astellas Pharma US Inc$140
  • Novo Nordisk$130
  • Pfizer$120
  • Takeda Pharmaceuticals U.S.A., Inc.$106
  • plus $604 from 16 others

What the payments were for

  • Food & beverage$1,65894%
  • Education$1096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,767 in reported general payments places this provider in the 65th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$165,977
Medicare patients
285
Services billed
2,434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$93,008
JardianceEmpagliflozin63$58,598
TrulicityDulaglutide27$46,253
XareltoRivaroxaban46$30,985
OzempicSemaglutide18$29,833
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$27,917
RybelsusSemaglutide11$27,475
LinzessLinaclotide21$19,491
MyrbetriqMirabegron27$18,432
KerendiaFinerenone11$16,762
FarxigaDapagliflozin Propanediol12$14,343
Tresiba Flextouch U-200Insulin Degludec15$13,958
EntrestoSacubitril/Valsartan16$13,511
JanuviaSitagliptin Phosphate12$13,290
Levothyroxine Sodium689$9,836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$120$101,928145 claims
Boehringer IngelheimJardiance$74$58,59863 claims
Novo NordiskOzempic, Rybelsus$130$57,30829 claims
Lilly USA, LLCTrulicity$518$46,25327 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$98$38,35154 claims
AbbVieLinzess$149$19,49121 claims
Astellas Pharma US IncMyrbetriq$140$18,43227 claims
BayerKerendia$61$16,76211 claims
MerckJanuvia$96$13,29012 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$106$5,57512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →